Kareem Mohamed Abu-Elmagd | |
|---|---|
 | |
| Born | Kareem Mohamed Abu-Elmagd, June 16, 1952 |
| Nationality | Egypt,United States |
| Alma mater | Mansoura University |
| Occupation | Professor of surgery |
| Children | Adam and Ahmed |
| Medical career | |
| Field | Transplant Surgery, Gut Rehabilitation |
| Institutions | Case Western Reserve University -Cleveland Clinic |
| Sub-specialties |
|
Kareem Abu-Elmagd (born June 16, 1952) is an Egyptian-American surgeon practicing abdominalorgan transplantation anddigestive system surgery.[1][2] He is best known for development of clinical intestinal andmultivisceral transplantation and its subsequent approval byMedicare.[3] He served as the president of the Intestinal Transplant Association.[4]
Abu-Elmagd was born inMansoura, the capital ofDakahlia Governorate in 1952.[5] In 1976 he obtained his medical degree atMansoura University School of Medicine. In 1987 earned his PhD in liver diseases and portal hypertensive surgery through a joint collaboration betweenEmory University inAtlanta and Mansoura University.[6] In 1989, he joined theUniversity of Pittsburgh to obtain clinical fellowship in transplantation surgery.[7] In 2001, he was promoted to professor of surgery at the University of Pittsburgh.[4]
In 1989, he was introduced to the field of organ transplantation by the late professorThomas E. Starzl. , the father of modern transplantation.[8] after that in 1990, Abu-Elmagd and his colleagues launched an intestinal and multivisceral transplant program which performed more than 450 intestine transplants surgery.[9] As of 2020, Abu-Elmagd is professor of surgery at Case-Western Reserve University and the director of the gut rehabilitation and transplantation center at the Cleveland clinic.[10][11][12] With more than 400 peer review scientific publications, as of 2020, his work has been cited close to 20,000 times between 2009 and 2017.[13]
Abu-Elmagd participated in performing the first successfulintestinal transplantation undertacrolimus in 1990 at the University of Pittsburgh[14] Later being a participant in the establishment of the clinical utility of tacrolimus in 1991.[15] He was a part of the team which demonstrated the immune-protective effect of the concomitantlytransplanted liver and the deleterious effect ofDSA on the visceral allograft.[16] His research led to the establishment ofMedicare coverage for intestinal and multivisceral transplant in the United States.[17] Abu-Elmagd pioneered or introduced surgical techniques and procedures, for correction ofintestinal malrotation in children and adults, replacing the historicLadd's procedure.[18][19][20][21] Another technique developed by him utilized the patient's own gut for the effective management of gut failure, eliminating the need for intravenous nutrition commonly calledTPN. An algorithm with a predictive model was established to guide clinicians, health care providers, payers and patients to achieve the best and most cost effective outcome, eliminating the need for gut transplantation.[better source needed][22]
Abu-Elmagd is the founder of the “Kareem Abu-Elmagd Transplant and Gut Foundation” national institute for patient care, clinical training, medical education and research in Egypt.[23][24]
In 2019 he performed apro bono operation for a 24-year-old woman from Bangladesh who had been suffering severe abdominal pain for a long time, without any known diagnosis. Her case involved reorganizing her intestines.[25]
{{cite journal}}: CS1 maint: multiple names: authors list (link)